Miguel A. Molina-Vila
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 15, 2026
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical research.
Journal: Molecular cancer
Published: January 24, 2024
Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways.
Journal: Translational oncology
Published: October 30, 2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.
Journal: Molecular cancer
Published: February 27, 2023
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 15, 2021
Panels and models for accurate prediction of tumor mutation burden in tumor samples.
Journal: NPJ precision oncology
Published: November 16, 2020
Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform.
Journal: Scientific reports
Published: October 22, 2020
Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells.
Journal: Translational oncology
Published: July 07, 2020
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 13, 2019
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.
Journal: Nature communications
Published: August 20, 2018
Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 06, 2018
Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
Journal: Mutation research. Reviews in mutation research
Published: November 22, 2017
Showing 1-12 of 12
Last Updated: 09/26/2026